Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. CRWV
8. MSFT
9. MH
10. DLMAF

Go back to Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease
INSMED (NASDAQ: INSM) Delayed: 97.17 +0.45 (0.47%)
Previous Close $96.72    52 Week High $19.30 
Open $95.12    52 Week Low $9.02 
Day High $98.00    P/E N/A 
Day Low $93.92    EPS $-1.69 
Volume 986,922